Forbion Capital Partners Archives — Page 2 of 2

Gotham Therapeutics adds Dr Holger Reithinger to its Board along with announcing its launch with raising $54m Series A funding

October 10, 2018October 10, 2018

– USA, NY – Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, debuted today with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R.…

Prexton Therapeutics announces Marco Boorsma and Alan O’Connell to Board along with raising €29m Series B financing

July 16, 2021February 7, 2017

– SWITZERLAND, Geneva – Prexton Therapeutics announced today that it has closed a €29m Series B financing round co-led by Forbion Capital Partners and Seroba Life Sciences.…

NeRRe Therapeutics strengthens its Board along with raising £23m Series B financing

December 20, 2018January 5, 2017

– UK, Stevenage – NeRRe Therapeutics, a clinical-stage company developing a unique portfolio of neurokinin receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity, announced it has raised £23 million in an oversubscribed Series B financing round.…